GSK (NYSE:GSK) Stock Rating Lowered by StockNews.com

GSK (NYSE:GSK) was downgraded by research analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a note issued to investors on Tuesday.

Other equities research analysts also recently issued research reports about the stock. Deutsche Bank Aktiengesellschaft downgraded shares of GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Guggenheim lowered shares of GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. Finally, Jefferies Financial Group lowered GSK from a “buy” rating to a “hold” rating and dropped their target price for the stock from $53.00 to $39.50 in a research report on Tuesday, November 12th. Seven research analysts have rated the stock with a hold rating, one has assigned a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $43.25.

GSK Stock Performance

NYSE GSK opened at $33.44 on Tuesday. GSK has a 1-year low of $31.72 and a 1-year high of $45.92. The business’s 50-day simple moving average is $33.93 and its 200-day simple moving average is $37.90. The firm has a market capitalization of $69.30 billion, a P/E ratio of 21.71, a P/E/G ratio of 1.47 and a beta of 0.63. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53.

Institutional Investors Weigh In On GSK

Several institutional investors and hedge funds have recently modified their holdings of GSK. Patriot Financial Group Insurance Agency LLC raised its position in shares of GSK by 9.2% in the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 17,910 shares of the pharmaceutical company’s stock valued at $606,000 after purchasing an additional 1,502 shares during the period. Perigon Wealth Management LLC lifted its stake in shares of GSK by 5.0% in the fourth quarter. Perigon Wealth Management LLC now owns 10,115 shares of the pharmaceutical company’s stock valued at $338,000 after buying an additional 484 shares during the period. Foundations Investment Advisors LLC grew its holdings in shares of GSK by 15.8% during the 4th quarter. Foundations Investment Advisors LLC now owns 11,717 shares of the pharmaceutical company’s stock worth $396,000 after purchasing an additional 1,595 shares in the last quarter. Blue Trust Inc. increased its holdings in GSK by 16.7% in the 4th quarter. Blue Trust Inc. now owns 12,505 shares of the pharmaceutical company’s stock valued at $423,000 after buying an additional 1,785 shares during the period. Finally, Grimes & Company Inc. bought a new stake in GSK in the fourth quarter valued at about $4,731,000. Institutional investors and hedge funds own 15.74% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.